Introduction {#Sec1}
============

Advances in cancer detection and treatment over the past 20 years have led to considerable improvements in cancer survival \[[@CR1], [@CR2]\]. Consequently, the number of people living with a history of cancer -- "cancer survivors" - is steadily increasing \[[@CR1]\]. Some cancers are increasingly thought of as chronic diseases that require evidence based multidisciplinary care for the prevention and management of comorbidities and sequelae \[[@CR3]--[@CR6]\].

Recent evidence has demonstrated that cancer survivors are at increased risk of cardiovascular disease (CVD) compared to the general population \[[@CR7]\] and that in certain populations (e.g. breast cancer survivors) CVD competes with cancer as the leading cause of death \[[@CR8], [@CR9]\]. This is likely to be due to shared risk factors (e.g. obesity and tobacco use) and potential cardiotoxic effects of systemic therapies and radiotherapy \[[@CR10], [@CR11]\]. It has been suggested that sub-optimal primary prevention may also be responsible \[[@CR12], [@CR13]\]. In the absence of specific cardiovascular risk prevention guidelines targeted at cancer survivors, such individuals would be expected to follow strategies recommended for the general population, i.e. reducing lifestyle-related risk factors, and pharmacological management of lipid and blood pressure \[[@CR14]\]. Since 2005, UK guidelines on primary CVD prevention (Additional file [1](#MOESM1){ref-type="media"}: Table S1) have recommended all people with high cardiovascular risk (i.e. 10 year predicted risk ≥20%) be offered statin therapy \[[@CR15]\]. Current risk assessment tools do not take possible additional risks associated with previous cancer into account, and may under-estimate vascular risk among cancer survivors. Statin uptake rates in the general population appear to be low, with a number of studies finding that only around one fifth to one third of patients at high cardiovascular risk were actually prescribed a statin \[[@CR16]--[@CR19]\]. To our knowledge, equivalent statin uptake rates in cancer survivors have not previously been quantified.

In order to best target initiatives to improve gaps in survivorship care, we need to confirm whether cardiovascular risk prevention strategies are being followed in this vulnerable population, and whether cancer survivors persist with long-term medications intended to reduce their cardiovascular risk. We therefore aimed to compare use of lipid-lowering drugs between cancer survivors and control patients with no previous cancer, specifically focusing on prescribing of statins to those scored as high CV risk; and the time to statin discontinuation, among those starting a statin.

Methods {#Sec2}
=======

Data source and main study population {#Sec3}
-------------------------------------

We conducted a longitudinal population-based open cohort study using Clinical Practice Research Datalink (CPRD) GOLD data. CPRD GOLD is a primary care database containing the anonymised medical records for over 15 million patients from 674 general practices in the United Kingdom (UK) \[[@CR20]\]. CPRD GOLD data, which are collated daily from participating practices that use Vision software, include information on demographics, symptoms, tests, diagnoses, and prescriptions, and are subject to data quality checks. Diagnoses in CPRD are typically recorded using National Health Service (NHS) Read codes. Approximately 7% of the UK population are included, with patients broadly representative of the UK general population in terms of age, sex and ethnicity \[[@CR20]\]. In the UK, the General Practitioner (GP) is the first point of contact and "gatekeeper" for most non-emergency NHS care; the vast majority of the population is registered with a GP \[[@CR21]\].

The study period was 1st January 2005 to 31st December 2013 because during this period national guidelines (Additional file [1](#MOESM1){ref-type="media"}: Table S1) remained constant in recommending statin therapy for people with predicted cardiovascular risk ≥20% over 10 years, for primary prevention. Patients who were 40 years or older during the study period and had at least 12 months of research quality CPRD follow-up prior to entering the cohort were included; follow-up began on the latest of 1/1/2005, the patient's 40th birthday, or the date on which 12 months of follow-up had been accumulated in CPRD; follow-up ended on the earliest of 31/12/2013, the last data collection date, or the end of follow-up in CPRD. Patients with a CVD event (Additional file [2](#MOESM2){ref-type="media"}: Table S2) prior to entering the study were excluded (as our focus was on primary CVD prevention).

Read code lists to identify cancer diagnoses were developed using the methodology described in a previous study \[[@CR22]\]. All person-time was categorised into "never-cancer", "first year post-cancer diagnosis" and "≥ 1 year post-cancer diagnosis". Person-time in the ≥1 year post-cancer diagnosis category made up the cancer survivor group, while "never-cancer" person-time made up the control group. Person-time in the first year post-cancer diagnosis was not analysed further. People could contribute to more than one of the comparison groups, if they developed cancer during follow-up, but could only contribute to one exposure group at any given moment of follow-up. From this overall study population, sub-cohorts were defined to address each of our objectives, as described in the sections below.

Descriptive analysis {#Sec4}
--------------------

Baseline characteristics were described for the overall study population and sub-populations (defined below). We also described the proportion of patients with at least one measurement recorded in the past 5 years for each of: blood pressure (diastolic and systolic recorded on the same day), lipids (total cholesterol and/or high-density lipoprotein cholesterol (HDL) and/or cholesterol/HDL ratio), and 10 year predicted cardiovascular risk score (Framingham, QRisk, ASSIGN, Joint British Society (JBS), or unspecified; Read terms used to identify cardiovascular risk scores are included in Additional file [3](#MOESM3){ref-type="media"}: Table S3). This description of blood pressure/lipids/risk score recording was stratified by cancer survivor / control status, gender and specific points of age (namely at age 45, and in steps of 5 years up to 75); and within strata, was restricted to individuals under follow-up at the given age and with at least 5 years of prior follow-up in CPRD.

Uptake of statins among those recorded as high CVD risk {#Sec5}
-------------------------------------------------------

To assess uptake of statin therapy among patients with high recorded CVD risk, all patients from the overall study population with a first ever Read code or quantitative record indicating predicted 10 year cardiovascular risk of ≥20% in CPRD and no previous statin use were included in the 'high cardiovascular risk cohort'. To exclude patients with previous high risk scores, patients were required to have at least 12 months of research quality follow-up in CPRD prior to the first high risk score record. Patients were excluded if their follow-up ended during the 31 day period after the high cardiovascular risk score, leaving inadequate eligible time to assess prescription of a statin within 1 month. For this analysis, patients were grouped as cancer survivors or controls based on their status on the date of their first high CVD risk record. The outcome was statin uptake, defined as having a first prescription for statin therapy (defined using the codes in Additional file [4](#MOESM4){ref-type="media"}: Table S4) within 31 days of the first high cardiovascular risk score. The association between cancer survivorship and statin uptake was assessed using logistic regression. First, the unadjusted association was estimated, then we adjusted for age at baseline (i.e. at first high cardiovascular risk score, in 10 year categories) and gender as a-priori confounders. The following potential confounders were considered one at a time: practice Index of Multiple Deprivation quintile (a proxy for socio-economic status) \[[@CR23]\]; body mass index (BMI, categorised as underweight (\< 18.5 kg/m^2^), healthy weight (18.5-25 kg/m^2^) and overweight/obese (\> 25 kg/m^2^)); total cholesterol (categorised as normal (\< 5 mmol), moderate-high (5-8 mmol) and high (\> 8 mmol)); smoking status (never, current, ex-smoker); alcohol consumption (non-drinker, ex-drinker, high/medium/low/unknown-level current drinker); chronic kidney disease (CKD), diabetes, and chronic liver disease at baseline (both defined using Read codes); and calendar time (split into 2005--07, 2008--10, 2011--13 to account for the marked increase in statin prescribing demonstrated in previous CPRD research over the study time period \[[@CR24]\]). These covariates were only included in the final model if the absolute change to the odds ratio (OR) was greater than 10% when the single variable was added to the unadjusted model. Only participants with complete data for the relevant confounder were included in the stepwise testing analyses (adjusted and comparative a-priori models).

We investigated whether calendar period modified the association between cancer and initiation of a statin by adding calendar period to the model as an interaction term - the stratified ORs were assessed and a likelihood ratio test was used to compare the models with and without the interaction term. There was not considered to be any a priori reason to test for any other interactions.

Time to statin discontinuation among those starting a statin {#Sec6}
------------------------------------------------------------

To assess statin persistence, patients from the overall study population who started a statin for primary prevention (i.e. with no previous CVD record) during the study time period were included in the 'statin initiator cohort'. To exclude prevalent statin users, patients were required to have at least 12 months of research quality follow-up prior to first prescription. For this analysis, patients were grouped as cancer survivors or controls based on their status on the date of their first statin prescription. The outcome was the time from statin initiation to first cessation of therapy, calculated from prescription records. The end date of each prescription was calculated by dividing the quantity prescribed by the daily dose where this information was available. Where duration could not be calculated, the modal prescription duration (28 days) was assumed. If there was no repeat prescription within 90 days after the estimated end date of a prescription, a patient was defined as having ceased therapy at the estimated end date. A multivariate Cox model was built, with time since statin initiation as the underlying time scale and with age (time-updated), gender, BMI, smoking status and diabetes (time updated) included as a priori confounders. All regression analyses were restricted to individuals with complete data for these confounders. Other candidate confounders were assessed and added to the model using the same model-building strategy as described for the analysis of statin uptake (above).

We investigated an interaction between cancer survivorship and calendar period as uptake of statins varies over time and drivers of this may differ in cancer survivors versus the general population. We also considered heterogeneity by time since cancer diagnosis. The proportional hazards assumption was assessed by testing for an interaction between cancer survivor status and time since statin initiation (categorised as \< 0.5, 0.5--1, \> 1--2, \> 2 years). In a sensitivity analysis, the Cox model time scale was switched to age (to control more closely for age), and time since initiation was adjusted for as a time-varying covariate. Robust standard errors were used in all analyses to account for clustering at GP practice level.

Results {#Sec7}
=======

Overall, 3,369,849 individuals aged 40 years or over during the study period 2005 to 2013 were included in the main study cohort (Fig. [1](#Fig1){ref-type="fig"}). Of the main study cohort 131,676 contributed person-time to the cancer survivors (exposed) and 3,324,152 to the general population controls (unexposed). Demographics and baseline characteristics of the study populations are described in Table [1](#Tab1){ref-type="table"}.Fig. 1Flow chart of included study participantsTable 1Baseline characteristics for the main study cohort and sub-populations by cancer survivor (\> = 1 year) statusMain Study Cohort^a^High Cardiovascular Risk Cohort^b^Statin Initiator Cohort^c^Cancer SurvivorControlCancer SurvivorControlCancer SurvivorControl*n* = 131,676*n* = 3,324,152*n* = 4202*n* = 113,035*n* = 12,142*n* = 366,280*n* (%)*n* (%)*n* (%)*n* (%)*n* (%)*n* (%)Sex Male58,587 (44.7)1,618,820 (48.70)2659 (63.3)80,264 (71.0)5959 (49.1)194,430 (53.1) Female72,823 (55.3)1,705,299 (51.30)1543 (36.7)32,771 (29.0)6183 (50.9)171,848 (46.9)Age (years) Median (IQR)66.5 (57.5--75.5)50.5 (42.1--62.3)69.1 (64.2--72.9)64.2 (58.4--69.8)68.9 (62.4--75.1)62.6 (54.9--70.2) 40--4914,117 (10.7)1,529,272 (46.0)27 (0.6)5410 (4.8)351 (2.9)45,132 (12.3) 50--5924,564 (18.6)775,972 (23.3)368 (8.8)27,121 (24.0)1630 (13.4)96,664 (26.7) 60--6938,078 (28.9)521,777 (15.7)1815 (43.2)50,847 (45.0)4393 (36.2)125,540 (34.3) 70--7933,983 (25.8)303,231 (9.1)1765 (42.0)26,713 (23.6)4086 (33.7)73,598 (20.1) 80+20,934 (15.9)193,900 (5.8)227 (5.4)2944 (2.6)1682 (13.7)25,346 (6.9)BMI (kg/m2) Mean (SD)26.9 (5.3)26.9 (5.3)28.3 (4.8)27.8 (5.1)28.2 (5.4)28.7 (5.6)  \< 18.52748 (2.1)48,109 (1.4)50 (1.2)897 (0.8)131 (1.1)2906 (0.8) 18.5--2546,037 (35.0)1,130,838 (34.0)1127 (26.8)27,294 (24.2)3175 (26.9)86,962 (24.5)  ≥ 2574,375 (56.5)1,736,648 (52.2)2925 (69.6)81,734 (72.3)8504 (72.0)265,128 (74.7) Missing8516 (6.5)408,557 (12.3)100 (2.4)3113 (2.8)332 (2.7)11,285 (3.1)Cholesterol (mmol/L) Mean (SD)5.3 (1.2)5.4 (1.1)5.7 (1.0)5.8 (1.1)6.0 (1.3)6.1 (1.3) Normal (\< 5)42,503 (32.3)796,230 (23.9)898 (21.4)21,543 (19.1)2242 (18.7)58,780 (16.2) Mod (5--8)62,529 (47.5)1,405,997 (42.3)3137 (74.6)85,221 (75.4)8965 (74.8)278,848 (76.9) High (\> 8)1704 (1.5)38,297 (1.2)92 (2.2)3316 (2.9)775 (6.47)25,032 (6.9) Missing24,940 (18.9)1,083,578 (32.6)75 (1.8)2955 (2.6)157 (1.29)3640 (1.0)Smoking status Never46,606 (35.4)1,358,706 (40.9)1194 (28.4)29,306 (25.9)3729 (30.7)118,728 (32.4) Ex61,969 (47.1)965,510 (29.1)2133 (50.8)46,494 (41.2)6572 (54.1)166,482 (45.5) Current22,627 (17.2)885,915 (26.6)875 (20.8)37,190 (32.9)1840 (15.2)80,841 (22.1) Missing474 (0.4)114,021 (3.4)\< 545 (0.0)\< 5299 (0.1)Alcohol status (non- ex- current drinker) Non25,030 (19.0)577,211 (17.4)742 (17.7)18,139 (16.1)2500 (27.3)75,516 (27.5) Ex3778 (2.84)74,249 (2.2)162 (3.9)4079 (3.6)447 (4.9)13,002 (4.7) Current  light48,354 (36.7)1,042,681 (31.3)1629 (38.8)40,996 (36.3)4868 (53.1)140,039 (51.0)  moderate4776 (3.6)106,934 (3.2)224 (5.3)5904 (5.2)503 (5.5)15,837 (5.8)  heavy5025 (3.8)150,372 (4.5)254 (6.0)9229 (8.2)562 (6.1)19,668 (7.2)  unknown2819 (2.1)74,769 (2.3)117 (2.8)4193 (3.7)280 (3.1)10,747 (3.9) Missing41,894 (31.8)1,297,936 (39.0)1074 (25.6)30,495 (27.0)2982 (24.6)91,474 (25.0)Medical history Diabetes12,045 (9.2)153,405 (4.6)187 (4.5)5308 (4.7)2239 (18.4)69,156 (18.9) CKD9577 (7.3)28,419 (0.9)368 (8.8)5465 (4.8)1450 (12.0)24,464 (6.7) Chronic liver disease2223 (1.7)39,429 (1.2)75 (1.8)7975 (1.8)221 (1.8)6378 (1.7)Index of Multiple Deprivation quintile 1 (least)16,993 (12.9)298,566 (9.0)641 (15.2)12,842 (11.4)1697 (11.1)40,458 (11.1)  212,043 (12.9)340,205 (10.2)588 (14.0)13,616 (12.6)1607 (13.2)43,074 (11.8)  318,708 (14.2)384,484 (11.6)545 (13.0)14,211 (12.6)1655 (13.6)48,491 (13.2)  464,007 (48.6)1,978,653 (59.5)1894 (45.1)57,464 (50.8)5615 (46.2)188,142 (51.4) 5 (most)14,985 (11.4)322,244 (9.7)434,534 (12.7)14,902 (13.2)1586 (13.1)46,115 (12.6)Calendar year 2005--0762,916 (47.8)2,423,116 (72.9)623 (14.8)23,020 (20.4)4105 (33.8)156,589 (42.8) 2008--1034,416 (26.1)471,289 (14.2)1681 (40.0)48,349 (42.8)4310 (35.5)124,339 (33.9) 2011--1334,344 (26.1)429,747 (12.9)1898 (45.2)41,666 (36.9)3727 (30.7)85,352 (23.3)^a^Covariates were measured at baseline (or closest recording) defined in the 'main study cohort' as the date of the start of unexposed (non-cancer) and exposed (≥ 1 year post cancer diagnosis) follow-up time. Patients in the Main Study Cohort could contribute person-time to exposed and unexposed cohorts^b^Baseline was defined in the 'high cardiovascular risk cohort' as the date of the first high cardiovascular risk score. Patients could only be included in one of the comparison cohorts^c^Baseline was defined in the 'statin initiator cohort' as the date of the first statin prescription. Patients could only be included one of the comparison cohorts. If a non-cancer patient developed cancer while on statin therapy they were censored

Cancer survivors were older on average than controls (median: 67 years vs. 51 years), and a higher proportion were females (55.3% vs. 51.3%). As patients enter the cancer survivor group later than the general population control group, the proportion of patients followed up from later calendar years was greater in the cancer survivor group (26.1% vs. 12.9% for 2011--2013). The baseline prevalence of diabetes and CKD were substantially higher among cancer survivors compared with controls (9.2% vs 4.6% respectively for diabetes, and 7.3% vs 0.9% for CKD). Figure [2](#Fig2){ref-type="fig"} describes the proportion of individuals from the full study population with a BP, cholesterol measurement, or a cardiovascular risk score recorded at least once in the past 5 years, by age, gender and exposure status; a table of the same results presented numerically is provided in Additional file [5](#MOESM5){ref-type="media"}: Table S5. Overall, the highest level of monitoring was observed for BP (range: 60.0% to 97.2%), followed by cholesterol (range: 32.6% to 80.1%). BP and cholesterol monitoring were consistently higher in cancer survivors than controls, across all ages and gender with the exception of cholesterol monitoring in women which appeared to be similar between cancer survivors and controls. There was suboptimal recording of cardiovascular risk scores for both sexes and in all age groups, regardless of cancer status (range: 5.6% to 21.3%). Cancer survivors tended to have either similar or marginally better recording of cardiovascular risk compared to controls of the same age and gender. We repeated these analyses post-hoc restricting to patients without CKD or diabetes, in case baseline differences in these diseases affected the comparison between cancer survivors and controls. Similar patterns were seen.Fig. 2Proportion (%) of individuals with a cardiovascular risk measures recorded in the past 5 years. • Blood pressure recorded = a diastolic and systolic BP recorded on the same day at least once in the past 5 years. • Cholesterol recorded = total cholesterol and/or high-density lipoprotein cholesterol and/or cholesterol/HDL ratio recorded at least once in the past 5 years. • Cardiovascular risk score (CVR) recorded = 10 year predicted cardiovascular risk (Framingham, QRisk, ASSIGN, Joint British Society (JBS), or unspecified) recorded at least once in the past 5 years. • Study population = 3,369,849 patient main study cohort

Uptake of statins among those recorded as high CVD risk {#Sec8}
-------------------------------------------------------

The 'high cardiovascular risk cohort' included 118,012 individuals (Fig. [1](#Fig1){ref-type="fig"}). Of these, 4202 individuals were cancer survivors at the time of their first high risk score and 113,035 were controls; cancer survivors were more likely than controls to be older (median age 69.1 vs 64.2 years), female (36.7% vs. 29.0%), current non-smokers (79.2% vs. 67.1%), less deprived (29.2% vs 24.0% in the lower two deprivation quintiles) and to have CKD (8.8% vs. 4.8%; Table [1](#Tab1){ref-type="table"}, middle columns). There were also small but statistically significant differences in cholesterol and alcohol status between the groups.

Nine hundred sixty-eight of 4202 cancer survivors (23.0%) and 26,606 of 113,035 controls (23.5%) initiated a statin within a month of their first high cardiovascular risk score. There was no evidence of association between cancer survivorship and statin initiation in the initial unadjusted analysis: OR 0.97 (95% CI: 0.90--1.05, *p* = 0.443, Table [2](#Tab2){ref-type="table"}). There was evidence that statin initiation was more likely among females, those with BMI ≥25 kg/m^2^, total cholesterol \> 5 mmol/L, ex-smokers, and those with diabetes or CKD, and less common in people aged over 80 years, heavy drinkers, underweight individuals, and those in later calendar periods. None of the tested covariates individually changed the association between cancer survivorship and statin initiation by more than 10%; the maximum change being 1.5%. Therefore only age and gender were included in the final logistic regression model as a priori confounders associated with both cancer status and statin initiation. The final adjusted odds ratio was 0.98 (95% CI: 0.92--1.05, *P* = 0.626) (Table [2](#Tab2){ref-type="table"}). There was no evidence that the association between cancer survivorship and statin initiation differed by calendar period (p-interaction = 0.709).Table 2Associations between cancer survivorship and covariates, and statin initiation among the high cardiovascular risk cohortTotal nInitiates statin n (%)Crude OR (95% CI)*p*-valueAdjusted^a^ OR (95% CI)*p*-valueCancer status (binary) Non-cancer113,03526,606 (23.54)10.4431 Cancer survivor4202968 (23.04)0.97 (0.90--1.05)0.98 (0.92--1.05)0.626Sex Males82,92318,902 (22.79)1\< 0.0011\< 0.001 Females34,3148672 (25.27)1.15 (1.11--1.18)1.19 (1.15--1.23)Age (years) 40--4954371301 (23.93)1\< 0.0011\< 0.001 50--5927,4896402 (23.29)0.97 (0.90--1.04)0.96 (0.89--1.03) 60--6952,66212,760 (24.23)1.02 (0.92--1.12)1.00 (0.90--1.10) 70--7928,4786624 (23.26)0.96 (0.87--1.06)0.92 (0.83--1.01) 80+3171487 (15.36)0.58 (0.47--0.71)0.53 (0.43--0.65)BMI (kg/m2)  \< 18.5948136 (14.35)0.62 (0.53--0.73)\< 0.001 18.5--2528,4216050 (21.29)1  ≥ 2584,65920,779 (24.54)1.2 (1.17--1.24) Missing n (%)3213 (2.74)Cholesterol (mmol/L) Normal (\< 5)22,4692910 (12.95)1\< 0.001 Moderate - High (5--8)88,27422,838 (25.87)2.36 (2.25--2.49) High (\> 8)34351750 (50.95)7.1 (6.48--7.78) Missing n (%)3059 (2.61)Smoking status Never smoker30,5006863 (22.5)1\< 0.001 Ex-smoker48,62711,971 (24.62)1.12 (1.08--1.17) Current smoker38,0658738 (22.96)1.03 (0.97--1.09) Missing n (%)45 (0.04)Alcohol status Non-drinker18,8814598 (24.35)1\< 0.001 Ex-drinker42411064 (25.09)1.04 (0.94--1.15) Current drinker  light42,62510,455 (24.53)1.01 (0.96--1.06)  moderate61281475 (24.07)0.98 (0.91--1.06)  heavy94832039 (21.50)0.85 (0.77--0.94)  amount unknown43101009 (23.41)0.95 (0.85--1.06) Missing n (%)31,569 (26.93)Medical history Diabetes54951853 (33.72)1.7 (1.57--1.85)\< 0.001 Chronic kidney disease58331568 (26.88)1.21 (1.11--1.31)\< 0.001 Chronic liver disease2050453 (22.10)0.92 (0.83--1.02)0.120Index of Multiple Deprivation quintile 1 (least deprived)13,4833133 (23.24)1\< 0.001 214,2043143 (22.13)0.94 (0.75--1.17) 314,7563510 (23.79)1.03 (0.82--1.29) 459,35813,626 (22.96)0.98 (0.84--1.16) 5 (most deprived)15,4364162 (26.96)1.22 (0.95--1.56)Calendar year 2005--0723,6436257 (26.46)1\< 0.001 2008--1050,03011,461 (22.91)0.83 (0.80--0.86) 2011--1343,5649856 (22.62)0.81 (0.78--0.84)^a^Adjusted for a priori confounders (age and gender). No other covariates changed the association between cancer survivorship and statin initiation by more than 10%

Persistence on statin therapy for primary prevention of CVD {#Sec9}
-----------------------------------------------------------

Three hundred eighty thousand eight hundred fifty-five individuals were newly prescribed a statin for primary prevention (Fig. [1](#Fig1){ref-type="fig"}). Twelve thousand one hundred forty-two were cancer survivors at the time of statin initiation, 366,280 were controls and 2433 were excluded from the analysis as statins were initiated within 1 year of cancer diagnosis. Characteristics of the two groups are described in Table [1](#Tab1){ref-type="table"} (right hand columns); differences between the groups were similar to those observed in the high cardiovascular risk cohort. In the statin survivor and control group, 6141 (50.6%) and 190,044 (51.9%) individuals discontinued statin therapy over a median follow-up time of 1.56 and 1.65 years respectively. Following exclusion of subjects with missing a-priori confounder values, 366,771 subjects (96.9%) were included in the Cox regression models. The overall discontinuation rates were 20.7 and 19.8 per 100 person years for the cancer survivor and general population groups. The unadjusted hazard ratio (HR) for association between cancer survivorship and statin discontinuation was 1.02 (95%CI: 0.96--1.09, *p* = 0.50; Table [3](#Tab3){ref-type="table"}). Associations between covariates and statin discontinuation are also shown in Table [3](#Tab3){ref-type="table"}.Table 3Associations between cancer survivorship covariates, and time to statin cessation among statin initiatorsStatin initiatorsNumber of events^a^Person-Years of Follow-Up (hundreds)Crude Rate (per 100 Person-Years)Unadjusted HR^b^*p*-valueAdjusted HR^c^*p*-valuen%Cancer status (binary) Non-cancer354,96196.8183,84492.519.810.50210.02 Cancer survivor11,8103.259622.820.71.02 (0.96--1.09)1.07 (1.01--1.12)Sex Males193,64652.898,24650.619.41\< 0.0011\< 0.001 Females173,12547.291,56044.720.51.05 (1.04--1.06)1.05 (1.04--1.06)Age (yrs) 40--4944,08812.026,4539.827.11\< 0.0011\< 0.001 50--5995,53926.151,09924.520.80.81 (0.80--0.82)0.80 (0.79--0.82) 60--69126,57034.560,76334.917.40.69 (0.68--0.70)0.66 (0.65--0.67) 70--7975,42520.637,64720.518.40.73 (0.71--0.75)0.68 (0.67--0.70) 80+25,1496.913,8445.724.20.89 (0.85--0.93)1.14 (1.05--1.24)BMI (kg/m2)  \< 18.530350.817730.628.91.25 (1.20--1.30)\< 0.0011.18 (1.14--1.23)\< 0.001 18.5--2590,12324.648,25122.621.311  ≥ 25273,61374.6139,78272.119.40.92 (0.91--0.93)0.94 (0.93--0.95)Cholesterol (mmol/L) Normal (\< 5)59,40216.229,00315.818.41\< 0.001 Mod-High (5--8)279,53876.2146,48972.420.21.10 (1.09--1.11) High (\> 8)24,7786.812,5336.818.51.01 (0.99--1.03) Missing30530.8Smoking status Never smoker117,65832.161,05531.119.61\< 0.0011\< 0.001 Ex-smoker169,39346.284,17245.318.60.94 (0.93--0.96)0.98 (0.96--0.99) Current smoker79,72021.744,57919.023.51.16 (1.14--1.17)1.13 (1.12--1.15)Alcohol status Non-drinker76,63720.940,34920.020.21\< 0.001 Ex-drinker13,2393.667833.618.90.95 (0.92--0.97) Current drinker  light143,35139.172,29139.218.40.93 (0.90--0.95)  moderate16,0974.481984.318.90.95 (0.91--0.99)  heavy19,7205.410,7774.722.81.09 (1.07--1.12)  amount unknown10,8693.057722.820.31.01 (0.96--1.05) Missing86,85823.7Medical history Diabetes70,99019.434,52019.917.30.87 (0.85--0.88)\< 0.0010.83 (0.82--0.84)\< 0.001 Chronic kidney disease25,2786.912,2435.721.41.01 (0.98--1.05)\< 0.001 Chronic liver disease64401.833951.423.51.12 (1.08--1.16)\< 0.001IMD quintile 1 (least deprived)40,76911.121,05211.718.01\< 0.001  243,25611.822,09711.918.61.01 (0.97--1.06)  348,50413.224,90813.119.11.03 (0.98--1.09)  4187,80651.298,03046.121.31.11 (1.06--1.17) 5 (most deprived)46,43612.723,71912.618.81.03 (0.97--1.09)Calendar year 2005--07155,75842.586,41256.615.31\< 0.001 2008--10124,78834.067,53830.122.51.27 (1.26--1.29) 2011--1386,22523.535,8568.741.31.52 (1.50--1.55)^a^Events = first cessation of statin therapy defined as a no further prescriptions 90 days after the expected end date of the last prescription^b^Cox model with time since study entry (i.e. statin initiation) as the timescale^c^Adjusted for a priori confounders \[age (time-updated), gender, body mass index, smoking status and diabetes (time-updated)\]. No other covariates changed the association between cancer survivorship and statin cessation by more than 10%.All regression models are restricted to patients with complete data for a-priori confounders

Only the a priori confounders (age, sex, BMI, smoking, diabetes status) were included in the final model as none of the other covariates changed the HR for cancer survivorship by more than 10%. The maximum change was 3.6% with the inclusion of calendar year (HR = 1.02, 0.98--1.06). The final adjusted Cox regression model provided evidence that the risk of statin discontinuation was higher in cancer survivors than controls (HR 1.07 95% CI: 1.01--1.12; *p* = 0.02). The same model built with age as the underlying timescale and adjusted for time since statin initiation gave similar results (HR = 1.07, 1.01--1.13, p = 0.02). There was no evidence of interaction between cancer survivorship and calendar period (p-interaction = 0.44) or of differences in the association according to time since cancer diagnosis (*p* = 0.70). However, the association between cancer survivorship status and statin discontinuation appeared to change with time since statin initiation (i.e. evidence of non-proportional hazards, *p* \< 0.001): there was no evidence of an effect of cancer survivorship on statin discontinuation in the first 6 months (HR = 1.00 (0.96--1.04)) or at 6 months to 1 year of therapy (HR = 1.01 (0.94--1.08)); from the second year of therapy onwards, there was good evidence that the risk of statin discontinuation rate was higher among cancer survivors (HR = 1.09 95% CI = 1.02--1.17; *p* = 0.008 for the 2nd year of therapy, and HR = 1.22 95% CI =1.16--1.28; *p* \< 0.001 for \> 2 years after initiation, Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Association between cancer survivorship^i^ and statin discontinuation, by time since statin initiation (index date timescale) ^ii^. Legend: \[i\] cancer survivors (\> 1 year after a cancer diagnosis) compared to never cancer controls. \[ii\] From a Cox proportional hazards model with time since statin initiation as the timescale, adjusted for 'current' age, gender, BMI, smoking and diabetes mellitus (time updated)

Discussion {#Sec10}
==========

There was a low uptake of statins among cancer survivors with a high recorded cardiovascular risk, with only 23% starting a statin within 31 days of their high risk score record; however, there was no evidence of any difference in uptake between cancer survivors and non-cancer controls, after adjusting for age and sex, either overall or within specific calendar periods. Cancer survivors did appear to be more likely to discontinue statins than controls, in particular after the first year since statin initiation, with the risk of discontinuation 9% (95% CI 2--17%) higher during the second year since statin initiation (*p* = 0.013) and 22% (95% CI 16--28%) higher after 2 years or more on therapy (p \< 0.001).

This is the first large observational database study to report on initiation of statin therapy in cancer survivors. Neither are there any directly comparable studies on statin cessation rates in cancer survivors versus non-cancer or general population controls. However, our finding of a greater tendency for cancer survivors to stop statin therapy is in line with a self controlled retrospective cohort study in 36,149 breast cancer patients that used a large health care claims database to compare adherence to oral medications in the 1 year prior to diagnosis with 0.5--1.5 years after diagnosis \[[@CR25]\]. The study found adherence to hyperlipidemia medications (based on medication possession ratio) declined from 83.2 to 57.1% (*P* \< 0.001). Adherence to long term medications including statins tends to wane with time \[[@CR26], [@CR27]\], which might explain the findings from Yang et al.'s after vs before comparison. Statin cessation rates for controls in this study were higher than an earlier study in CPRD (20.1 vs. 13 per 100 person years, respectively), possibly explained by the earlier study excluding people with \< 2 statin prescriptions and those with \< 1 year of follow-up after their first statin script \[[@CR28]\]. One other retrospective cohort study compared statin discontinuation by indication (primary versus secondary prevention) in 539 poor prognosis cancer patients \[[@CR29]\]. Over 60% of patients continued filling statin scripts during the 2 years after diagnosis and use was similar regardless of indication. The study can only be generalised to poor prognosis patients and those who start statin therapy before a cancer diagnosis, was underpowered to compare number of refills after diagnosis, and lacked a control group.

Our cohort study was large in size, with sufficient power to produce precise estimates and detect small associations. CPRD is broadly representative of the UK population in terms of age, sex and ethnicity \[[@CR20]\]. Cancer diagnoses in CPRD have been previously validated by comparing with national cancer registration and hospitalization and death certificate data: \> 90% of cancers in CPRD were confirmed in other data sources, and \> 90% of nationally registered cancers were captured in CPRD \[[@CR30], [@CR31]\]. Statin prescribing is likely to be extremely well captured in CPRD because the vast majority of statin prescribing takes place in primary care, and GP prescription data are captured automatically at the point of issue.

Our study also has some limitations. There were some missing data in BMI and smoking, leading to omission of patients from the statin cessation regression analysis (in which only complete cases were included); this could lead to selection bias if the association between the exposure, outcome and covariates was different in patients with and without missing data. However, the amount of missing data for BMI and smoking was low (≤ 3.1%) and this is unlikely to have significantly impacted our results.

Despite the excellent prescribing data in CPRD, statin initiation might have been underestimated because over the counter therapy (OTC) is not captured in CPRD. However based on OTC sales and consumer interviews, this is not expected to be large issue \[[@CR32]\]. Equally, in the statin initiation analysis, it was impossible to decipher from the data available whether a statin was offered and refused by the patient versus not offered. Misclassification of statin cessation may also have occurred for individuals who did not fill the statin prescription and individuals who received the drug but not take it. This may lead to an underestimation of statin cessation in cancer survivors and controls. To our knowledge, there is no evidence that this would differ between groups, so this non-differential misclassification may have led to an underestimation of the difference in cessation between the groups. While the analyses of statin initiation and cessation attempted to control for confounding, some potential confounding factors were not consistently available for individual patients, including ethnicity, and family history of CVD, so there is some potential for residual confounding. Ethnic minorities tend to have lower cancer rates \[[@CR33]\] and are more likely to discontinue statins \[[@CR34]\] which could also produce negative confounding, not controlled for in this study.

During cancer treatment and survivorship, patients are likely to visit their GP more regularly and measurement of individual cardiovascular risk factors is increased. This represents an opportunity to re-inforce the importance of preventative measures in a patient group that is thought to be at increased risk of CVD. Our findings suggest that this opportunity has been missed over the study period (2005--2013). Initiatives such as cancer treatment summaries and survivorship care plans aim to increase GP and patient awareness of potential adverse events associated with cancer treatment \[[@CR35], [@CR36]\]. Better implementation of these initiatives may improve uptake of measures designed to prevent CVD.

Our study highlights opportunities for further research. We considered cancer survivors in a single group, but future research might look at whether our results are dependent upon type of cancer history. Our descriptive analyses demonstrated suboptimal levels of cardiovascular risk score recording in both cancer survivors and never cancer controls. Future studies are warranted estimating the number of cancer survivors who are not prescribed statins although they are at high risk of CVD, whether or not they have a risk score recorded. Qualitative studies might be carried out to further investigate the reasons for similarly low levels of statin initiation and slightly higher statin cessation rates among cancer survivors after 1 year compared to the general population. Other aspects of cardiovascular risk prevention should also be assessed, including initiation of antihypertensive therapies in at risk patients.

Conclusions {#Sec11}
===========

We observed low uptake of statins in both cancer survivors and controls with no history of cancer, with no evidence of difference between the two groups. Cessation of statin use is substantial and may be somewhat higher after 1 year of treatment in cancer survivors than in the general population. Further research might explore the reasons for this and investigate a wider range of preventative measures. There may be an opportunity to mitigate the suspected higher cardiovascular risk in the growing population of cancer survivors by improving uptake of lipid-lowering treatment and persistence on therapy.
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